PL2744798T3 - Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera - Google Patents

Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera

Info

Publication number
PL2744798T3
PL2744798T3 PL12756402T PL12756402T PL2744798T3 PL 2744798 T3 PL2744798 T3 PL 2744798T3 PL 12756402 T PL12756402 T PL 12756402T PL 12756402 T PL12756402 T PL 12756402T PL 2744798 T3 PL2744798 T3 PL 2744798T3
Authority
PL
Poland
Prior art keywords
tauopathies
alzheimer
disease
treatment
derivatives useful
Prior art date
Application number
PL12756402T
Other languages
English (en)
Inventor
Gerard Griffioen
Giuseppe Cecere
Matthias Nettekoven
Katrien Princen
Hasane Ratni
Mark Rogers-Evans
Walter Vifian
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Publication of PL2744798T3 publication Critical patent/PL2744798T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL12756402T 2011-08-17 2012-08-17 Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera PL2744798T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11177742 2011-08-17
PCT/EP2012/066136 WO2013024168A1 (en) 2011-08-17 2012-08-17 Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
EP12756402.9A EP2744798B1 (en) 2011-08-17 2012-08-17 Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease

Publications (1)

Publication Number Publication Date
PL2744798T3 true PL2744798T3 (pl) 2016-08-31

Family

ID=46826450

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12756402T PL2744798T3 (pl) 2011-08-17 2012-08-17 Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera

Country Status (9)

Country Link
US (2) US9187440B2 (pl)
EP (1) EP2744798B1 (pl)
JP (1) JP6051218B2 (pl)
CN (1) CN103649062B (pl)
AU (1) AU2012296804B2 (pl)
CA (1) CA2841037C (pl)
ES (1) ES2573299T3 (pl)
PL (1) PL2744798T3 (pl)
WO (1) WO2013024168A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841037C (en) * 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds
WO2025104092A1 (en) * 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
RU2396270C2 (ru) * 2005-01-07 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
EP1705474B1 (en) 2005-03-21 2010-04-28 F.Hoffmann-La Roche Ag Method for determining lipophilicity
WO2007005510A1 (en) * 2005-06-30 2007-01-11 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
AU2008215948A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EP2726470B1 (en) * 2011-07-01 2015-04-29 reMynd NV 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
CA2841037C (en) 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease

Also Published As

Publication number Publication date
US20160101102A1 (en) 2016-04-14
US9808456B2 (en) 2017-11-07
US9187440B2 (en) 2015-11-17
EP2744798B1 (en) 2016-03-30
ES2573299T3 (es) 2016-06-07
JP2014521737A (ja) 2014-08-28
AU2012296804A1 (en) 2014-01-30
US20140206699A1 (en) 2014-07-24
CN103649062B (zh) 2015-10-07
CA2841037A1 (en) 2013-02-21
CN103649062A (zh) 2014-03-19
JP6051218B2 (ja) 2016-12-27
CA2841037C (en) 2020-03-31
AU2012296804B2 (en) 2017-04-20
EP2744798A1 (en) 2014-06-25
HK1192848A1 (zh) 2014-09-05
WO2013024168A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
AP3807A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL223819A0 (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
TWI559929B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IL230441A0 (en) Diagnosis of Alzheimer's disease
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
PL2744798T3 (pl) Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera
SG11201406093VA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
IL239078A0 (en) Protein for use in the treatment of eye diseases
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
GB201101088D0 (en) L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease
HK1195902A (en) Compositions and methods for treating alzheimer's disease